Publications by authors named "G Ahmann"
Identifying biomarkers associated with disease progression and drug resistance are important for personalized care. We investigated the expression of 121 curated genes, related to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) responsiveness. We analyzed 28 human multiple myeloma (MM) cell lines with known drug sensitivities and 130 primary MM patient samples collected at different disease stages, including newly diagnosed (ND), on therapy (OT), and relapsed and refractory (RR, collected within 12 months before the patients' death) timepoints.
View Article and Find Full Text PDFSeventy-six FDA-approved oncology drugs and emerging therapeutics were evaluated in 25 multiple myeloma (MM) and 15 non-Hodgkin's lymphoma cell lines and in 113 primary MM samples. Ex vivo drug sensitivities were mined for associations with clinical phenotype, cytogenetic, genetic mutation, and transcriptional profiles. In primary MM samples, proteasome inhibitors, dinaciclib, selinexor, venetoclax, auranofin, and histone deacetylating agents had the broadest cytotoxicity.
View Article and Find Full Text PDFArticle Synopsis
- APY0201, a PIKfyve inhibitor, shows strong cellular cytotoxicity against multiple myeloma, confirmed through testing in 25 cell lines and 40% of 100 primary patient samples, especially in cases with trisomies and without t(11;14).
- When compared to other PIKfyve inhibitors, APY0201 demonstrated superior potency, effectively reducing cell viability at very low concentrations in a majority of tested cell lines.
- The treatment with APY0201 resulted in changes related to lysosomal function and autophagy, suggesting that its effectiveness in multiple myeloma may stem from disrupting these cellular processes, and establishing a predictive autophagy assay could help identify likely responsive patients.